¿¬±¸µ¿ÇâÁ¤º¸
Á¦¸ñ Àü¸³¼± ºñ´ëÁõ Ä¡·áÁ¦(5ARIs)ÀÇ ³²¼ºÀ¯¹æ¾Ï À§Çè¿äÀÎ ±Ô¸í
±Û¾´ÀÌ °ü¸®ÀÚ
÷ºÎÆÄÀÏ

 Àü¸³¼± ºñ´ëÁõ Ä¡·áÁ¦(5ARIs)ÀÇ ³²¼º À¯¹æ¾Ï À§Çè¿äÀÎ ±Ô¸í 

ÀÓ»óÁú¹®

³²¼ºÀÇ Àü¸³¼± ºñ´ëÁõ(benign prostatic hyperplasia (BPH) Ä¡·á¸¦ À§ÇØ Ã³¹æµÇ´Â 5-alpha reductase inhibitors (5ARIs)º¹¿ëÀÌ ³²¼º¿¡°Ô À¯¹æ¾ÏÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Â À§Çè¿äÀÎÀÌ µË´Ï±î?

±Ù°Å±â¹Ý ´äº¯

Finasteride¿Í Dutasteride¸¦ Æ÷ÇÔÇÑ 5-alpha reductase inhibitors (5ARIs)´Â ¾ç¼º Àü¸³¼± ºñ´ëÁõ (BPH), ÇϺοä·ÎÁõ»ó (LUTS) ¹× ¾Èµå·Î°Õ¼º Å»¸ð(AGA)¸¦ Ä¡·áÇϱâ À§ÇØ ÀϹÝÀûÀ¸·Î ó¹æµË´Ï´Ù. ±×·¯³ª ¹ß±âºÎÀü ¹× ¸®ºñµµ °¨¼Ò¿Í °°Àº 5ARIÀÇ Àß ¾Ë·ÁÁø ºÎÀÛ¿ë ÀÌ¿Ü¿¡µµ BPH¿¡ ´ëÇÑ 5ARIÀÇ È¿°ú¿¡ ´ëÇÑ ³²¼º ´ë»óÀÇ ¹«ÀÛÀ§ ½ÃÇè ´ëÁ¶¿¬±¸ (RCT)¿¡¼­ Finasteride 5mg ±º¿¡¼­ À¯¹æ¾ÏÀÇ ºóµµ°¡ ´õ ³ô¾ÒÀ½¿¡ ´ëÇÑ ¿¬±¸º¸°í°¡ ÀϺΠÀÖ¾ú½À´Ï´Ù. ±×·¯³ª º» ü°èÀû °íÂû ¿¬±¸°á°ú¸¦ ÅëÇØ ÀúÀÚµéÀº 5ARI°¡ ³²¼º Áý´Ü¿¡¼­ À¯¹æ¾ÏÀ» Áõ°¡½ÃŲ´Ù´Â Áõ°Å¸¦ ãÀ» ¼ö ¾ø¾ú°í, 5ARI°¡ ÀÌÀüÀÇ °¡¼³°ú´Â ´Þ¸® ¿¡½ºÆ®·Î°Õ È£¸£¸ó ¶ÇÇÑ Áõ°¡½ÃÅ°Áö ¾Ê´Â´Ù´Â °á·ÐÀ» ³»·È½À´Ï´Ù.

¼­ÁöÁ¤º¸

Five-Alpha Reductase Inhibitor and Breast Cancer Risk in Men: A Systematic Review, Annals of Dermatology, 2017³â 29±Ç 4È£ p.525 ~ p.528: DOI:

https://doi.org/10.5021/ad.2017.29.4.525

¿¬±¸¸ñÀû

5ARIsÀÌ ³²¼º¿¡°Ô À¯¹æ¾ÏÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Â À§Çè¿äÀÎÀÎÁö¸¦ ±Ô¸íÇÏ°íÀÚ ÇÔ

¿¬±¸¼³°è

ü°èÀû °íÂû(Systematic Review)

¿¬±¸´ë»ó

³²¼º 705,890¸í : 137,421¸í 5ARIs¿¡ ³ëÃâµÈ ½ÇÇ豺°ú 568,469¸í ´ëÁ¶±º

½ÃÇ豺 ÁßÀç

5-alpha reductase inhibitors (5ARIs) : 5ARI-exposed (137,421¸í)

´ëÁ¶±º ÁßÀç

non-exposed groups ( 568,469¸í)

Æò°¡ÁöÇ¥

Breast cancer risk

ÁÖ¿ä°á°ú

º» ü°èÀû °íÂû ¿¡¼­ ÀúÀÚµéÀº 5ARI°¡ ³²¼º Áý´Ü¿¡¼­ À¯¹æ¾ÏÀ» Áõ°¡½ÃŲ´Ù´Â Áõ°Å¸¦ ãÀ» ¼ö ¾ø¾ú°í, ÀÌÀü ¿¬±¸°¡¼³°ú´Â ´Ù¸£°Ô 5ARI Åõ¿©°¡ ¿¡½ºÆ®·Î°Õ È£¸£¸óÀ» Áõ°¡½ÃŲ´Ù´Â °á·ÐÀ» ³»¸®Áö ¾Ê¾Ò½À´Ï´Ù

±Ù°Å¼öÁØ

Moderate (The included studies were too heterogeneous to pool for a meta-analysis and only systematic review was done)

ÀÛ¼ºÀÚ

ÀÇ°úÇבּ¸Á¤º¸¼¾ÅÍ(MedRIC)

Copyright © 2016. Medical Research Information Center (MedRIC) Editors


2017-12-19 ¿ÀÈÄ 2:06:42, Á¶È¸¼ö : 2610